Skip to content
Back Home
  • Home
  • About Us
    • Our History
    • Our Science
    • Our Partners
  • Scientific Platforms
    • ADCs
    • Publications
  • Team
  • News
  • Contact
Back Home
  • Search
  • Home
  • About Us
    • Our History
    • Our Science
    • Our Partners
  • Scientific Platforms
    • ADCs
    • Publications
  • Team
  • News
  • Contact
Home » Uncategorized » Manhattan BioSolutions secures non-dilutive angel funding
Uncategorized

Manhattan BioSolutions secures non-dilutive angel funding

by Mbio2018|Published May 1, 2018

You may also like

Published May 12, 2020

Nascent Biotech and Manhattan BioSolutions Enter into Collaboration to Advance Vaccine Discovery and Development for COVID-19

San Diego, CA, May 12, 2020—Nascent Biotech, Inc (OTCQB: NBIO), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat cancers […]

Published June 25, 2024

Manhattan BioSolutions Partners to Advance Taxoids as Innovative ADC Payloads

Published September 9, 2020

Manhattan BioSolutions Announces Phase I SBIR Grant Award from the National Science Foundation

NEW YORK, NEW YORK, UNITED STATES, September 9, 2020 /EINPresswire.com/ — Manhattan BioSolutions, a biotechnology company focused on the discovery of the […]

Published November 1, 2018

Manhattan BioSolutions establishes new laboratory space at the JLabs JNJ Innovation incubator in New York City

Post navigation

  • Back to post list
  • Next post Manhattan BioSolutions has been awarded REACH grant from the New York State Center For Biotechnology at the Stony Brook University

© 2025 Manhattan BioSolutions – All rights reserved

Powered by WP – Designed with the Customizr theme